T1	Pregnancy_considerations 0 191	Women who are pregnant, lactating or breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of the first day of any study session
T2	Person 193 200	Smokers
T3	Competing_trial 391 481	Participation in any ongoing investigational drug trial/study or clinical drug trial/study
T4	Condition 494 531	chronic obstructive pulmonary disease
T5	Condition 535 549	cor pulmonale,
T6	Condition 567 596	decreased respiratory reserve
T7	Condition 598 605	hypoxia
T8	Condition 607 618	hypercapnia
T9	Condition 635 657	respiratory depression
*	OR T4 T5 T6 T7 T8 T9
T10	Measurement 694 708	HIV serologies
T11	Measurement 675 686;698 708	Hepatitis B serologies
T12	Measurement 675 684;688 689;698 708	Hepatitis C serologies
*	OR T10 T11 T12
T13	Scope 675 708	Hepatitis B, C and HIV serologies
T14	Value 666 674	positive
R1	Has_value Arg1:T13 Arg2:T14	
T15	Measurement 719 744	urine drug screening test
T16	Value 710 718	Positive
R2	Has_value Arg1:T15 Arg2:T16	
T17	Non-query-able 746 1020	Use of any prescription medication during the session 0 to 30 days or over-the counter medication e.g. antihistamines or topical corticosteroids (vitamin, herbal supplements and birth control medications not included) during the session 0 to 3 days before entry to the study
T18	Non-query-able 1022 1536	Use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator with 72 hours prior to dosing (e.g. antihistamines, systemic or topical corticosteroids (within 3 weeks prior to dosing), cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy
T19	Drug 1546 1574	monoamine oxidase inhibitors
T20	Temporal 1575 1597	21 days prior to study
T21	Reference_point 1592 1597	study
R3	Has_temporal Arg1:T19 Arg2:T20	
R4	Has_index Arg1:T20 Arg2:T21	
T22	Drug 1648 1659	pentazocine
T23	Drug 1661 1671	nalbuphine
T24	Drug 1675 1686	butorphanol
T25	Drug 1709 1722	buprenorphine
*	OR T22 T23 T24 T25
T26	Drug 1751 1767	anticholinergics
T27	Non-query-able 1820 1983	Consumption of beverages containing alcohol, grapefruit juice, Seville oranges, or quinine (e.g. tonic water) or foods containing poppy seeds in the last 72 hours.
T28	Non-query-able 1985 2072	Donation or loss of greater than one pint of blood within 60 days of entry to the study
T29	Condition 2112 2128	hypersensitivity
T30	Drug 2132 2140	fentanyl
T31	Drug 2142 2150	morphine
T32	Drug 2152 2159	codeine
T33	Drug 2161 2172	hydrocodone
T34	Drug 2174 2187	hydromorphone
T35	Drug 2189 2198	oxycodone
T36	Drug 2200 2211	oxymorphone
T37	Drug 2213 2223	naltrexone
T38	Drug 2227 2235	naloxone
T39	Device 2278 2282	TDDS
*	OR T30 T31 T32 T33 T34 T35 T36 T37 T38 T39
T40	Device 2284 2313	polyester/ethyl vinyl acetate
T41	Device 2315 2336	polyacrylate adhesive
T42	Device 2338 2355	silicone adhesive
T43	Device 2357 2371	dimethicone NF
T44	Device 2376 2386	polyolefin
*	OR T40 T41 T42 T43 T44
T45	Scope 2132 2386	fentanyl, morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, naltrexone or naloxone or any of the inactive ingredients in the TDDS (polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin
T46	Scope 2284 2386	polyester/ethyl vinyl acetate, polyacrylate adhesive, silicone adhesive, dimethicone NF, or polyolefin
R5	Subsumes Arg1:T39 Arg2:T46	
R6	Has_scope Arg1:T29 Arg2:T45	
T47	Condition 2409 2422	schizophrenia
T48	Condition 2432 2459	major psychiatric diagnosis
T49	Condition 2463 2477	mental illness
T50	Condition 2484 2500	major depression
*	OR T47 T48 T49
R7	Subsumes Arg1:T49 Arg2:T50	
T51	Condition 2547 2556	addiction
T52	Condition 2560 2565	abuse
T53	Qualifier 2539 2546	alcohol
T54	Qualifier 2531 2535	drug
*	OR T53 T54
T55	Scope 2531 2546	drug or alcohol
T56	Scope 2547 2565	addiction or abuse
R8	Has_scope Arg1:T56 Arg2:T55	
*	OR T51 T52
T57	Non-query-able 2567 2741	Any condition that would, in the opinion of the MAI, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
T58	Post-eligibility 2743 2803	Inability to communicate or cooperate with the investigators
T59	Non-query-able 2805 3125	Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application site (upper arm), sunburn, raised moles and scars, open sore, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug
T60	Non-query-able 3127 3461	Failure to pass opioid dependence challenge test on the first day study day of any study session (i.e., before taking the first dose of naltrexone hydrochloride). Each subject will be injected subcutaneously with naloxone hydrochloride (0.8 mg injection) and will be observed for 45 minutes for signs and symptoms of opioid withdrawal
T61	Non-query-able 3464 3755	Within 4 weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product or agents deemed to be immunosuppressive as determined by physician investigator
